

Date: April 25, 2025

To, Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai – 400 001	To, Listing Compliance Department National Stock Exchange of India Limited, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Bandra Kurla Complex, Bandra (E), Mumbai-400051
Scrip Code: 531146	SYMBOL: MEDICAMEQ

Reference: Outcome of the Meeting of Board of Directors, held on April 24, 2025, of Medicamen Biotech Limited (“the Company”) in accordance with Regulation 30 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Subject: Corrigendum to the Outcome of the Meeting of Board of Directors of Medicamen Biotech Limited (“the Company”) in accordance with Regulation 30 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

This is in reference to the Outcome of the Board Meeting dated April 24, 2025 submitted in terms of the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (**Listing Regulations, 2015**). In this regard, we wish to inform your good office that the allotment made to Veralogix Holdings (PTY) Ltd is 5,99,995 Equity Shares, however in the outcome filed on April 24, 2025, the number of shares was inadvertently mentioned as 6,00,000 Equity Shares due to a typographical error.

The Company has already filed the revised outcome on April 25, 2025 mentioning the correct number of Equity Shares allotted.

You are requested to take the above on records.

Thanking You,
Yours Sincerely,
For **Medicamen Biotech Limited**

Parul Choudhary
Company Secretary & Compliance Officer